Go Pro
TSE:BHC

Bausch Health Companies Q3 2024 Earnings Report

Bausch Health Companies logo
C$6.40 +0.06 (+0.95%)
As of 04:00 PM Eastern

Bausch Health Companies EPS Results

Actual EPS
C$1.53
Consensus EPS
C$1.43
Beat/Miss
Beat by +C$0.10
One Year Ago EPS
N/A

Bausch Health Companies Revenue Results

Actual Revenue
$3.42 billion
Expected Revenue
$3.36 billion
Beat/Miss
Beat by +$63.06 million
YoY Revenue Growth
N/A

Bausch Health Companies Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bausch Health Companies Earnings Headlines

Equities Analysts Set Expectations for TSE:BHC Q2 Earnings
A 50-year dollar arrangement just ended - what it means for you
In 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a little-known arrangement that tied global oil trade to the U.S. dollar for 50 years. On June 9, 2024, it quietly expired. Garrett Goggin, CFA, CMT, believes this dollar reset could hit stocks, real estate, and retirement accounts hard - with inflation potentially running 10% to 15% for years. He has identified a small group of gold stocks he thinks are positioned to benefit as the dollar system shifts.tc pixel
Bausch Health Companies (TSE:BHC) Upgraded at Jefferies Financial Group
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (TSE:BHC) (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

View Bausch Health Companies Profile